TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11694699
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro before dinner
Study: 11694699
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro after meals
Study: 11694699
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin before meals
Study: 8198411
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (500 mg/kg)
Study: 2898256
Drug: ICI 118,551,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118,551, 50 mg orally given thrice daily
Study: 28912210
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of evidence-based medications
Study: 23621289
Drug: Enteral feeds
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral feeds 80 mL/kg/day started within 1 h of birth, increased by 20 mL/kg/day to 180 mL/kg/day, no intravenous fluids
Study: 23621289
Drug: Intravenous fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluids 50 mL/kg/day started along with enteral feeds 30 mL/kg/day within 1 h of birth, increased by 20 mL/kg/day to 180 mL/kg/day
Study: 16404409
Drug: Insulin quartiles
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin quartiles
Study: 14504182
Drug: Clopidogrel with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel with aspirin dose ≤100 mg
Study: 14504182
Drug: Clopidogrel with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel with aspirin dose 101-199 mg
Study: 14504182
Drug: Clopidogrel with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel with aspirin dose ≥200 mg
Study: 14504182
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with aspirin dose ≤100 mg
Study: 14504182
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with aspirin dose 101-199 mg
Study: 14504182
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with aspirin dose ≥200 mg
Study: 8962903
Drug: Enteral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutritional support supplement (1680 calories, 294 grams of carbohydrates, 36.9 grams of fat, 43.5 grams of protein in branched chain amino acids)
Study: 8962903
Drug: Enteral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutritional support supplement
Study: 1463361
Drug: Long course
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long course DEC treatment (6, 7, 8, 9 or 10 mg kg‐1 b.w. divided into three doses daily for seven days)
Study: 1463361
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course DEC treatment (15 mg kg‐1 b.w. once daily for one, two or three days)
Study: 1463361
Drug: DEC treatment
Normalized name: Zodryl DEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC treatment for Brugia malayi infections
Study: 1463361
Drug: DEC treatment
Normalized name: Zodryl DEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC treatment for mixed infections
Study: 1463361
Drug: DEC treatment
Normalized name: Zodryl DEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC treatment for Wuchereria bancrofti infections
Study: 31012786
Drug: Non-malaria control
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-malaria control vaccine (C3C)
Study: 31012786
Drug: Non-malaria control
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-malaria control vaccine
Study: 29315079
Drug: Spermidine supplementation
Normalized name: spermidine
DrugBank: Spermidine (DB03566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spermidine supplementation (1.2 mg/day)
Study: 17617289
Drug: Tizanidine capsule
Normalized name: Tizanidine Capsules
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tizanidine capsule (4 mg)
Study: 17617289
Drug: Tizanidine tablet
Normalized name: Tizanidine Tablets
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tizanidine tablet (reference)
Study: 17617289
Drug: Tizanidine capsule
Normalized name: Tizanidine Capsules
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tizanidine capsule and tablet
Study: 15767241
Drug: Other statins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other statins (atorvastatin, simvastatin, pravastatin)
Study: 12231416
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg oral clodronate
Study: 12231416
Drug: 1600 mg
Normalized name: glycerin 1600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg oral clodronate
Study: 12231416
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg intravenous clodronate
Study: 10150325
Drug: Atenolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (120 mg/d orally)
Study: 10150325
Drug: Ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (5 mg/d orally)
Study: 2039377
Drug: Daily prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily prednisone therapy (1.5 mg/kg per day and 0.75 mg/kg per day)
Study: 796739
Drug: Alternate-day prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alternate-day prednisone therapy
Study: 2039377
Drug: Daily prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily prednisone therapy
Study: 31090551
Drug: Multimodal prehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal prehabilitation program (in-hospital high-intensity endurance and strength training, high-protein nutrition and supplements, smoking cessation, psychological support)
Study: 28071141
Drug: CHoBI7 intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHoBI7 intervention (1-week handwashing with soap and water treatment)
Study: 24158335
Drug: Mandibular two-implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular two-implant overdentures (IOD)
Study: 21130593
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose thiamine therapy
Study: 11588903
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of ground flaxseed
Study: 11588903
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of ground flaxseed
Study: 11588903
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of ground flaxseed
Study: 19271419
Drug: Imipramine 50
Normalized name: trimipramine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 50 mg daily
Study: 2762082
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of visual and auditory input
Study: 31400049
Drug: High-dose valacyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose valacyclovir
Study: 25601966
Drug: Capecitabine 800
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 800 mg/m² twice daily throughout the 21-day cycle (Ccont)
Study: 25601966
Drug: Capecitabine 1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine 1,250 mg/m² twice daily for 2 weeks on and 1 week off (Cint)
Study: 24009092
Drug: Low-dose chest
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose chest CT (LDCT)
Study: 24009092
Drug: Low-dose chest
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose chest CT (LDCT) with PSFR cutoffs
Study: 23106890
Drug: Losartan 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 150 mg daily
Study: 9269694
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg daily
Study: 16630454
Drug: rhBNP (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhBNP (0.15 microg/kg bolus intravenous injection followed by 0.0075 microg.kg(‐1).min(‐1) for 24 hours, n = 105)
Study: 16630454
Drug: NIT (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIT (starting at 10 microg/min and increasing 5 microg/min each time till clinical effective dose for 24 hours, n = 104)
Study: 9032580
Drug: Flosulide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flosulide (20 mg twice a day)
Study: 3538843
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g protein
Study: 15486961
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g glucose
Study: 3538843
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g protein + 50 g glucose
Study: 26957232
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment applied on frozen embryo before transfer)
Study: 24632110
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for SAD, 16 weekly sessions of individual CBT.
Study: 19781591
Drug: CPP-ACP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPP-ACP treatment (Tooth Mousse, GC Corp.) for 60 min x 7 days with 2-step self-etching primer adhesive (Clearfil SE Bond, Kuraray Medical)
Study: 19781591
Drug: CPP-ACP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPP-ACP treatment (Tooth Mousse, GC Corp.) for 60 min x 7 days with 'all-in-one' adhesive (G-Bond, GC Corp.)
Study: 19781591
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (untreated dentine) with 2-step self-etching primer adhesive (Clearfil SE Bond, Kuraray Medical)
Study: 19781591
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (untreated dentine) with 'all-in-one' adhesive (G-Bond, GC Corp.)
Study: 19563393
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg daily (S80)
Study: 18441323
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg and simvastatin 10 mg daily (E10/S10)
Study: 10089069
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (THP‐COP) containing pirarubicin (30 mg/m2; day 1)
Study: 10089069
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (modified CHOP) containing doxorubicin (30 mg/m2; day 1)
Study: 10089069
Drug: Regimen C
Normalized name: ASPIRIN 81 mg ORAL TABLET, CHEWABLE [Bayer Aspirin Regimen Chewable Low Dose Aspirin Orange]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen C (THP‐COPE) including etoposide (80 mg/m2; day 1) in addition to regimen A
Study: 7744384
Drug: Acetaminophen oral
Normalized name: acetaminophen Oral Film
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen oral drop (1000 mg)
Study: 7744384
Drug: Acetaminophen tablet
Normalized name: Acetaminophen Tablets
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen tablet (1000 mg)
Study: 2721259
Drug: terbutaline, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: terbutaline, 15 mg daily for five weeks
Study: 24949564
Drug: Naltrexone (NTX;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (NTX; 25 mg once daily)
Study: 23507293
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) - three manualized sessions including one physical activity exposure session
Study: 15596721
Drug: Midazolam injection
Normalized name: midazolam Injection
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam injection
Study: 9004057
Drug: Clozapine 300
Normalized name: clozapine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine 300 mg or 600 mg
Study: 7680833
Drug: Cortisol infusion
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol infusion (2 micrograms.kg‐1.min‐1)
Study: 3925746
Drug: Intravenous isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous isosorbide dinitrate (ISDN)
Study: 30732125
Drug: Apatinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (500 mg/d) + chemotherapy
Study: 30732125
Drug: Apatinib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib + chemotherapy
Study: 25156125
Drug: No subgingival
Approvals — FDA: no, EMA: no, PMDA: no
Description: No subgingival treatment (NT)
Study: 19346194
Drug: HT treatment
Normalized name: Night Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HT treatment group (2 mg 17beta‐estradiol + 1 mg norethisterone acetate)
Study: 16940448
Drug: Acipimox (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (250 mg thrice daily)
Study: 15234826
Drug: Thyroid-stimulating hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid-stimulating hormone (TSH) testing
Study: 18476190
Drug: Grepafloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grepafloxacin (400 mg, single oral dose)
Study: 18476190
Drug: Cefixime (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (400 mg, single oral dose)
Study: 21840169
Drug: Video-enhanced voice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-enhanced voice therapy using portable digital media players with clinician and self-videos
Study: 21840169
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care voice therapy with written homework descriptions
Study: 16455288
Drug: Oral Balance
Normalized name: Biotene Oral Balance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Balance gel delivered by slow release via a novel intra‐oral device
Study: 16455288
Drug: Oral Balance
Normalized name: Biotene Oral Balance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Balance gel in bolus form
Study: 16455288
Drug: Oral Balance
Normalized name: Biotene Oral Balance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Balance gel (both forms)
Study: 8855797
Drug: Flutamide, testolactone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide, testolactone, reduced hydrocortisone dose (from 12.9 to 7.9 mg/m2 day), and fludrocortisone
Study: 8855797
Drug: Hydrocortisone and
Normalized name: hydrocortisone and mydriatics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone and fludrocortisone treatment
Study: 1613128
Drug: verapamil (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil (120 mg every 8 hr)
Study: 1613128
Drug: diltiazem (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: diltiazem (90 mg every 8 hr)
Study: 1613128
Drug: labetalol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol (200 mg every 12 hr)
Study: 31246522
Drug: High-dose cytarabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine, daunorubicin, and etoposide (HD-ADE, n = 133)
Study: 31246522
Drug: High-dose cytarabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine, daunorubicin, and etoposide (HD-ADE)
Study: 20133929
Drug: Prednisolone 40
Normalized name: prednisolone 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 40 mg for 7 days
Study: 17394656
Drug: Hypothetical preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothetical preventive drug treatment with heart attack postponement of 1 month
Study: 17394656
Drug: Hypothetical preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothetical preventive drug treatment with heart attack postponement of 6 months
Study: 17394656
Drug: Hypothetical preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothetical preventive drug treatment with heart attack postponement of 12 months
Study: 17394656
Drug: Hypothetical preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothetical preventive drug treatment with heart attack postponement of 2 years
Study: 17394656
Drug: Hypothetical preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothetical preventive drug treatment with heart attack postponement of 4 years
Study: 17394656
Drug: Hypothetical preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothetical preventive drug treatment with heart attack postponement of 8 years
Study: 10469936
Drug: Botulinum A
Normalized name: Botulinum antitoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum A toxin injections into the gastrocnemius muscle
Study: 10469936
Drug: Saline vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline vehicle injections into the gastrocnemius muscle
Study: 30679414
Drug: ALEM plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALEM plus tacrolimus (TAC) monotherapy (Group A)
Study: 30679414
Drug: ATG induction
Normalized name: ATGAM Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG induction plus TAC, mycophenolate mofetil (MMF) and steroids (Group B)
Study: 17445098
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BoNTA) at doses of 110 to 260 U per treatment cycle
Study: 15199622
Drug: Taizhi'an Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taizhi'an Capsule (TZA)
Study: 11429346
Drug: CaCl(2) 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaCl(2) 20 mg/kg and protamine 5 mg/kg mixed and infused over 10 min
Study: 11429346
Drug: CaCl(2) 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaCl(2) 10 mg/kg as a bolus followed by a 10‐min infusion of protamine 5 mg/kg and CaCl(2) 10 mg/kg
Study: 8181345
Drug: 0.9 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 percent saline solution (placebo)
Study: 3948547
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) albuterol (250 micrograms)
Study: 3948547
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) or subcutaneous albuterol (500 micrograms)
Study: 3948547
Drug: Combined data
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined data from all three albuterol routes
Study: 3948547
Drug: Subcutaneous epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous epinephrine (0.3 ml, 1:1,000)
Study: 3948547
Drug: IV albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV albuterol (250 micrograms), IM albuterol (500 micrograms), or subcutaneous albuterol (500 micrograms)
Study: 7020176
Drug: Prophylactic antithymocyte
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antithymocyte globulin (ATG) given in higher doses before signs of engraftment were evident.
Study: 31869853
Drug: Melatonin 20
Normalized name: melatonin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 20 mg along with conventional treatment
Study: 30307614
Drug: Sunscreen intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sunscreen intervention (SPF 15 applied at ≥ 2 mg cm−2)
Study: 30307614
Drug: Typical sunscreen
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical sunscreen use (own sunscreens applied at < 2 mg cm−2)
Study: 19826197
Drug: Computational method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computational method for incorporating patient motion into tomotherapy dose calculations
Study: 17160199
Drug: Lutein (L)
DrugBank: Lutein (DB00137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lutein (L) and zeaxanthin (Z) supplementation
Study: 12560305
Drug: Tramadol 75
Normalized name: traMADol 75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 75 mg plus droperidol 2.5 mg
Study: 12560305
Drug: Tramadol 75
Normalized name: traMADol 75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 75 mg plus clonidine 150 microg
Study: 8652903
Drug: CsA in
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA in capsule form
Study: 2011617
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g L-Tryptophan
Study: 2011617
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g L-Tryptophan
Study: 2011617
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g L-Tryptophan
Study: 2011617
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g L-Tryptophan
Study: 25559299
Drug: Stellate ganglion
Normalized name: Mastocarpus stellatus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stellate ganglion block (SGB) with 10 mL of 1% lidocaine
Study: 16169312
Drug: Enoxaparin, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin, 100 IU/kg subcutaneously twice daily (n = 220)
Study: 16169312
Drug: Tinzaparin, 175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin, 175 IU/kg subcutaneously once daily (n = 218)
Study: 17270002
Drug: Tegaserod 6
Normalized name: tegaserod 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 6 mg b.d.
Study: 11564007
Drug: Tegaserod 2
Normalized name: tegaserod 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 2 mg b.d.
Study: 14616170
Drug: Tegaserod 2
Normalized name: tegaserod 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 2 mg b.d. and Tegaserod 6 mg b.d.
Study: 6347752
Drug: Verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 120 mg t.i.d.
Study: 6125202
Drug: RX 781094
Approvals — FDA: no, EMA: no, PMDA: no
Description: RX 781094 at a dose of 0.1 mg/kg i.v.
Study: 6125202
Drug: RX 781094
Approvals — FDA: no, EMA: no, PMDA: no
Description: RX 781094 at a dose of 0.05 mg/kg i.v.
Study: 6125202
Drug: Clonidine at
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine at a dose of 0.1 mg and 0.2 mg i.v.